Trials / Recruiting
RecruitingNCT03288948
Binocular Amblyopia Treatment
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Retina Foundation of the Southwest · Academic / Other
- Sex
- All
- Age
- 4 Years – 10 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness of enhanced binocular amblyopia treatments in achieving a more complete and stable recovery.
Detailed description
To date, all studies of contrast-rebalanced binocular amblyopia treatment games used the same 10% per day contrast-increment that was designed for short-term intervention studies lasting 1-4 weeks; i.e., after 18 days of successful game play, both eyes viewed 100% contrast (no contrast-rebalancing).This study will investigate two alternative protocols designed to extend the game treatment period beyond 4 weeks to allow for more complete recovery of visual acuity. The new protocols will be compared with the original 10% contrast-increment game protocol in an 8-week 3-arm RCT to determine whether one or both of the new protocols is more effective than the current 10% increment. Based on pilot data, we expect about 40% of amblyopic children to achieve normal visual acuity in 8 weeks. In an effort to also promote recovery of binocular vision, children who attain ≤0.4 logMAR at 8 weeks will be enrolled in stereoacuity training at the 8-week visit for the next 4 weeks. Children with residual amblyopia (BCVA \>0.4 logMAR) at the 8-week visit will be provided with dichoptic movies for additional amblyopia treatment for another 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Binocular games for treatment of amblyopia | playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye |
Timeline
- Start date
- 2017-08-31
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2017-09-20
- Last updated
- 2026-02-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03288948. Inclusion in this directory is not an endorsement.